Abstract
Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. They have the potential advantage to spare COX-1 activity, thus reducing gastrointestinal toxicity, even when administered at high doses to improve efficacy. They are characterized by different pharmacodynamic and pharmacokinetics features. The higher biochemical selectivity of valdecoxib than celecoxib, evidenced in vitro, may be clinically relevant leading to an improved gastrointestinal safety. Interestingly, parecoxib, a pro-drug of valdecoxib, is the only injectable coxib. Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). Lumiracoxib, the most selective COX-2 inhibitor in vitro, is the only acidic coxib. The hypothesis that this chemical property may lead to an increased and persistent drug accumulation in inflammatory sites and consequently to an improved clinical efficacy, however, remains to be verified. Several randomized clinical studies suggest that the novel coxibs have comparable efficacy to nonselective NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and acute pain, but they share similar renal side-effects. The apparent dose-dependence of renal toxicity may limit the use of higher doses of the novel coxibs for improved efficacy. Large-size randomized clinical trials are ongoing to define the gastrointestinal and cardiovascular safety of the novel coxibs.
Keywords: valdecoxib, parecoxib, etoricoxib, lumiracoxib, cyclooxygenase, coxibs
Current Pharmaceutical Design
Title: Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Volume: 10 Issue: 6
Author(s): S. Tacconelli, M. L.. Capone and P. Patrignani
Affiliation:
Keywords: valdecoxib, parecoxib, etoricoxib, lumiracoxib, cyclooxygenase, coxibs
Abstract: Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. They have the potential advantage to spare COX-1 activity, thus reducing gastrointestinal toxicity, even when administered at high doses to improve efficacy. They are characterized by different pharmacodynamic and pharmacokinetics features. The higher biochemical selectivity of valdecoxib than celecoxib, evidenced in vitro, may be clinically relevant leading to an improved gastrointestinal safety. Interestingly, parecoxib, a pro-drug of valdecoxib, is the only injectable coxib. Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). Lumiracoxib, the most selective COX-2 inhibitor in vitro, is the only acidic coxib. The hypothesis that this chemical property may lead to an increased and persistent drug accumulation in inflammatory sites and consequently to an improved clinical efficacy, however, remains to be verified. Several randomized clinical studies suggest that the novel coxibs have comparable efficacy to nonselective NSAIDs in the treatment of osteoarthritis, rheumatoid arthritis and acute pain, but they share similar renal side-effects. The apparent dose-dependence of renal toxicity may limit the use of higher doses of the novel coxibs for improved efficacy. Large-size randomized clinical trials are ongoing to define the gastrointestinal and cardiovascular safety of the novel coxibs.
Export Options
About this article
Cite this article as:
Tacconelli S., Capone L.. M. and Patrignani P., Clinical Pharmacology of Novel Selective COX-2 Inhibitors, Current Pharmaceutical Design 2004; 10 (6) . https://dx.doi.org/10.2174/1381612043453108
DOI https://dx.doi.org/10.2174/1381612043453108 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Leukotrienes for the Treatment of COPD?
Inflammation & Allergy - Drug Targets (Discontinued) Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Meet Our Associate Editorial Board Member
Current Psychopharmacology Artificial Carriers: A Strategy for Constructing Antigenic/Immunogenic Conjugates
Current Topics in Medicinal Chemistry Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents miR-18a-3p Encourages Apoptosis of Chondrocyte in Osteoarthritis via HOXA1 Pathway
Current Molecular Pharmacology Editorial [Hot Topic: New Opportunities in Treatment of Arthritis (Guest Editor: Uday Saxena)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Endogenous Chemical Mediators in Anti-Inflammation and Pro-Resolution
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Strategies for Novel Therapeutic Approaches Targeting Cytokines and Signaling Pathways of Osteoclasto- and Osteoblastogenesis in the Fight Against Immune-Mediated Bone and Joint Diseases
Current Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Anti-HER2 VHH Targeted Fluorescent Liposome as Bimodal Nanoparticle for Drug Delivery and Optical Imaging
Recent Patents on Anti-Cancer Drug Discovery Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial
Reviews on Recent Clinical Trials Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism